for muscular dystrophy.
Maximum Tolerable Dose studies by Covance have shown that GsMTx4 is quite non-toxic.
A many-animal study of the D form of GsMTx4 on mdx mice is finishing at the Wellstone Center in WDC
Research at SUNY Buffalo has led to promising new drugs for therapy of muscular dystophy.
One of the compounds has been approved by the FDA as an orphan drug for the treatment of Duchenne's Muscular Dystrophy.
Above, you see JB, who is the catalyst for starting Tonus Therapeutics. More about JB.